Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer

Wethington, Stephanie L.; Armstrong, Deborah K.; Johnston, Fabian M.

doi:10.1001/jamasurg.2022.0156

Cited by 3 publications

(1 citation statement)

References 7 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hyperthermic intraperitoneal chemotherapy (HIPEC) during cytoreductive surgery offers a one-time opportunity to provide treatment to the peritoneal cavity, while the patient is anesthetized [6]. Although HIPEC retains the benefits and mitigates the concerns associated with intraperitoneal chemotherapy for ovarian cancer, the efficacy, safety, and treatment paradigm for its use remain controversial [2,6,7 ▪ ,8–11,12 ▪ ,13,14]. Our objective is to provide a history, rationale, and review of the use of HIPEC in the treatment of ovarian cancer…”

Section: Introductionmentioning

confidence: 99%

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Praiss

Moukarzel

Zivanovic

2022

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

Purpose of reviewOur objective is to provide a history, rationale, and review of the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer.Recent findingsIn the last decade, there has been an increase in the literature regarding HIPEC in the treatment of ovarian cancer. The rationale for HIPEC extends from earlier trials demonstrating improved survival using intraperitoneal chemotherapy. HIPEC provides a one-time opportunity for intraperitoneal chemotherapy at the time of cytoreduction and with the addition of hyperthermia. Cisplatin HIPEC has been demonstrated to have a survival benefit when used in the interval cytoreductive setting. In terms of safety, nephroprotection remains a key concern when administering HIPEC. Sodium thiosulfate provides nephroprotection and should be considered when performing HIPEC. Various institutions have created multidisciplinary protocols for administering HIPEC, which include operating room staff, nursing, anesthesia, pharmacy, and surgical teams.SummaryHIPEC has a role in the treatment paradigm of ovarian cancer. Currently, HIPEC is approved in the interval cytoreductive surgery setting. Further trials are needed to understand the appropriate timing, chemotherapeutic agents, and protocolization of HIPEC.

show abstract

Section: Introductionmentioning

confidence: 99%

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Praiss

Moukarzel

Zivanovic

2022

Current Opinion in Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

Response to: Correspondence on “Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods” by Lavoue et al

Navarro Santana,

Viveros-Carreño,

Ramirez

2024

Int J Gynecol Cancer

View full text Add to dashboard Cite

Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis

Tang

Huang

Zhang

et al. 2023

JCM

View full text Add to dashboard Cite

Objective: We aimed to compare the survival outcomes and adverse events of hyperthermic intraperitoneal chemotherapy (HIPEC), intraperitoneal chemotherapy (IP)and intravenous chemotherapy (IP)for primary advanced ovarian cancer. Methods: PubMed, CENTRAL (Cochrane Central Registry of Controlled Trials), Embase, Web of Science and Scopus were searched using multiple terms for primary advanced ovarian cancer, including randomized controlled trials and comparative studies in both Chinese and English (up to date 15 August 2022). Outcomes include overall survival, progression-free survival and adverse events. The data were pooled and reported as hazard ratio (HRs) with 95% confidence intervals. The Newcastle–Ottawa Scales were used to assess the risk of bias in the included comparative study. The Cochrane Collaboration’s Risk of Bias Tool was used for randomized controlled trials. Results: In total, 32 studies, including 6347 patients and 8 different platinum-based chemotherapy regimens, were included in this network meta-analysis. Our analysis results showed that HIPEC2 (carboplatin with area under the curve 10) exhibited a statistically significant OS benefit compared to IV, weekly dose-dense chemotherapy and HIPEC1 (cisplatin with 75/100 mg/m2). Intraperitoneal plus intravenous chemotherapy was associated with a statistically significantly better likelihood of overall survival compared to IV. For progression-free survival, our statistical results only suggest a better progression-free survival in ovarian cancer patients treated with HIPEC1 compared with weekly dose-dense chemotherapy. No evidence of difference was observed between the other comparison groups. Compared with the non-HIPEC group, HIPEC may had a higher incidence of electrolyte disturbances (≥grade 3). Conclusion: Our statistical analysis suggests that the groups receiving HIPEC2 had a better OS than the groups receiving IV, weekly dose-dense chemotherapy and HIPEC1. For PFS, our analysis only showed HIPEC1 is better than IV. Moreover, HIPEC may lead to a higher incidence of electrolyte disturbances (≥grade 3). HIPEC therapy for advanced ovarian cancer is currently controversial.

show abstract

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer

Abstract: Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.

Cited by 3 publications

References 7 publications

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?

Response to: Correspondence on “Complications of HIPEC for ovarian cancer surgery: evaluation over two time periods” by Lavoue et al

Comparative Survival Outcomes of Hyperthermic Intraperitoneal Chemotherapy, Intraperitoneal Chemotherapy and Intravenous Chemotherapy for Primary Advanced Ovarian Cancer: A Network Meta-Analysis

Contact Info

Product

Resources

About